Farmabios, Novasep and PharmaZell are now Axplora
Published on October 19, 2022
- Following the merger of Novasep and PharmaZell Group in April 2022, the Farmabios, Novasep and PharmaZell brands are now being unified under a single name.
- The merger brings together companies that share a track record of high quality, reliability and a complementary set of differentiated technologies.
- The name Axplora reflects the ambition to be the partner of choice for complex APIs. It conveys the Axplora spirit and agility, underpinned by an innovative mindset which drives the company and its employees.
Farmabios, Novasep and PharmaZell are one group
Raubling, 20 October 2022 – Farmabios, Novasep and PharmaZell officially announced today that they are coming together under the new brand Axplora. This announcement comes just 6 months after the closure of the merger of the Novasep and the PharmaZell Group. This marks the last step in the creation of Axplora, a leading Active Pharmaceutical Ingredients (API) manufacturing partner for pharmaceutical and biotechnology companies worldwide, with a long track record of reliably developing and scaling up complex production processes and delivering medicines on time and at scale, to the highest industry standards.
The creation of Axplora is the result of a carefully thought-out process: the new brand illustrates the innovative mindset driving the company and its employees. The tagline “Reliable partner. Agile explorer.” encapsulates the explorer spirit that the company fosters within the organisation and with our partners. It also refers to the pharmaceutical lifecycle to find API solutions in a reliable, safe, efficient, and sustainable way for patients.
With the Farmabios, Novasep and PharmaZell brands being unified under a single name, Axplora brings together companies that share a track record of high quality, reliability and a complementary set of differentiated technologies.
The merged company is leveraging technology and knowledge to deliver the full customer-centred lifecycle from innovation to generics. It will offer added security of supply for clients at the highest standards. With nine industrial sites in Europe and India and an R&D facility in the USA, its global footprint enables Axplora to optimize supply chain logistics.
Dr. Sylke Hassel, CEO of Axplora says: “I am very proud to reveal our new name today, Axplora, to take this step alongside our teams for our partners and customers. Under this new name, thanks to our talented staff, Axplora will provide the highest quality manufacturing solutions that will enable our customers to improve their patients’ quality of life, wherever they live in the world, and whatever their therapeutic need – across the full spectrum of the pharmaceutical development lifecycle.”
About Axplora
Axplora is a premier API manufacturing partner to the world’s leading patient-centric pharmaceutical and biotechnology companies, delivering top quality active ingredients on time and at scale, to the highest industry standards. Axplora is dedicated to helping pharmaceutical companies make critical medicines better, faster, safely, reliably, and sustainably benefitting patients worldwide. Leveraging its combined expertise and manufacturing capabilities across nine industrial sites in Europe and India, and an R&D facility in the USA, Axplora offers CDMO solutions to innovators for their small molecule and biomolecular active pharmaceutical ingredients, as well as products that address lifestyle-induced respiratory, inflammatory and liver diseases. Headquartered in Raubling (near Munich, Germany), Axplora employs 2,400 people around the world.
Press contact
Thomas Goldberg
+33 (0)4 37 28 20 52 | +33 (0)6 03 78 55 63
